Trial reportHeart (British Cardiac Society)2003
Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress.
Trial report in Heart (British Cardiac Society), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI.
Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)
Who cites it
17 citing papers in PubMed, 82 citations in OpenAlex.
- Oxidative Stress and DNA Damage Biomarkers in Heart Failure: A Systematic Review and Meta-Analysis.Antioxidants (Basel, Switzerland) · 2025Article
- Association of Systemic Thromboxane Generation With Risk of Developing Heart Failure.Journal of the American College of Cardiology · 2025Article
- Effects of Coenzyme QAntioxidants (Basel, Switzerland) · 2022Article
- A review of the "OMICS" for management of patients with obstructive sleep apnoea.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2020Review
- Superoxide dismutase activity as a predictor of adverse outcomes in patients with nonischemic dilated cardiomyopathy.Cell stress & chaperones · 2019Article
- OxInflammation: From Subclinical Condition to Pathological Biomarker.Frontiers in physiology · 2018Review
- Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload.Pulmonary circulation · 2016Article
- Cardiac biomarkers in children with congenital heart disease.World journal of pediatrics : WJP · 2015Review
- Biomarkers in heart failure: a clinical review.Heart failure reviews · 2010Review
- Novel eicosapentaenoic acid-derived F3-isoprostanes as biomarkers of lipid peroxidation.The Journal of biological chemistry · 2009Article
- Comparison of biomarkers of oxidative stress and cardiovascular disease in humans and chimpanzees (Pan troglodytes).Comparative medicine · 2009Article
- Serum oxidative stress level correlates with clinical parameters in chronic systolic heart failure patients.Clinical cardiology · 2009Article
- Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance.Frontiers in bioscience (Landmark edition) · 2009Review
- Article
- Levels of oxidative stress biomarkers in seminal plasma and their relationship with seminal parameters.BMC clinical pathology · 2007Article
- Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review.Heart failure reviews · 2006Review
- The putative role of isoprostanes in human cardiovascular physiology and disease: following the fingerprints.Heart (British Cardiac Society) · 2003Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate a novel marker of oxidative stress in patients with congestive heart failure (CHF). PATIENTS: 15 patients with mild CHF, 15 patients with severe CHF with acute exacerbation, and 15 control subjects.
main outcome measuresMeasurement of urinary 15-F2t-isoprostane, plasma brain natriuretic peptide (BNP), serum interleukin 6 (IL-6), and serum thrombomodulin concentrations. In patients with severe CHF, samples were taken at admission and 4, 7, and 14 days after admission.
resultsUrinary 15-F2t-isoprostane, plasma BNP, and serum IL-6 concentrations in patients with severe CHF were significantly higher than those in control subjects or in patients with mild CHF. However, concentrations of serum thrombomodulin, a marker of endothelial damage, were not different between patients with CHF and control subjects. In addition, urinary 15-F2t-isoprostane, plasma BNP, and serum IL-6 concentrations in patients with severe CHF gradually decreased in proportion to the severity of CHF during hospitalisation. Interestingly, urinary 15-F2t-isoprostane concentrations significantly correlated with plasma BNP concentrations and serum IL-6 concentrations, but not with serum thrombomodulin concentrations.
conclusionsUrinary 15-F2t-isoprostane concentrations increased in proportion to the severity of CHF in patients. This may be caused by increased 15-F2t-isoprostane production. These findings suggest that urinary 15-F2t-isoprostane may be a marker of morbidity as well as oxidative stress in patients with CHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.